Video Experimental Relacionado
Updated: Jun 21, 2026
09:46
Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
Published on: December 27, 2017
Factor de crecimiento derivado de plaquetas BB para el tratamiento de úlceras crónicas por presión
M C Robson1, L G Phillips, A Thomason
1Division of Plastic Surgery, University of Texas Medical Branch, Galveston 77555.
Lancet (London, England)
|January 4, 1992
Resumen
El factor de crecimiento humano recombinante tópico derivado de plaquetas-BB (rPDGF-BB) mejoró significativamente la curación de la úlcera crónica por presión a una dosis de 100 microgramos/ml. Este potente agente curativo de heridas no mostró efectos tóxicos en un estudio de fase I/II.
Área de la Ciencia:
- La Medicina Regenerativa es una Medicina Regenerativa.
- Dermatología Dermatología dermatología.
- Investigación de la curación de heridas.
Sus antecedentes:
- Las úlceras crónicas por presión presentan un desafío clínico significativo.
- Se necesitan estrategias terapéuticas efectivas para promover la regeneración de los tejidos blandos.
Objetivo del estudio:
- Evaluar la eficacia y seguridad del factor de crecimiento recombinante humano derivado de plaquetas-BB (rPDGF-BB) aplicado tópicamente en la curación de úlceras crónicas por presión.
- Para determinar la dosis óptima de rPDGF-BB para la cicatrización de heridas.
Principales métodos:
- Un estudio aleatorizado, de fase I/II, doble ciego, controlado con placebo.
- Veinte pacientes con úlceras crónicas por presión recibieron tratamiento diario durante 28 días.
- Los grupos de tratamiento incluyeron placebo y tres concentraciones de rPDGF-BB (1, 10, o 100 microgramos/ml).
Principales resultados:
- El grupo de 100 microgramos / ml rPDGF-BB demostró una respuesta de curación significativamente mayor en comparación con el placebo.
- El volumen de la úlcera disminuyó en un 6,4% en el grupo de dosis más alta de rPDGF-BB frente al 21,8% en el grupo de placebo después de 28 días.
- Las dosis más bajas de rPDGF-BB mostraron un efecto mínimo en la cicatrización de heridas. No se observaron efectos tóxicos.
Conclusiones:
- El rPDGF-BB tópico a 100 microgramos/ml es un agente potente y seguro para promover la curación de las úlceras crónicas por presión.
- Se justifica una mayor investigación sobre el rPDGF-BB para la reparación de heridas de tejidos blandos.
Videos de Conceptos Relacionados
00:49The Blood-brain Barrier
Overview
01:30Blood Pressure
Blood pressure (BP) is the pressure or force of blood exerted on the artery's walls as it circulates through the body. It is essential for maintaining blood flow throughout the body.
The average BP in an adult is typically around 120/80 mmHg (millimeters of mercury). In this measurement, the numerator (120) indicates the systolic pressure, which is the pressure in the arteries during the contraction of the heart's ventricles as blood is expelled. The denominator (80) represents the diastolic...
The average BP in an adult is typically around 120/80 mmHg (millimeters of mercury). In this measurement, the numerator (120) indicates the systolic pressure, which is the pressure in the arteries during the contraction of the heart's ventricles as blood is expelled. The denominator (80) represents the diastolic...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:24Blood Pressure
The movement of blood in a human body, commonly referred to as blood flow, is determined by the volume of blood that traverses a certain section of the bodily system per unit time. It is the rhythmic contraction of the heart's ventricles that primarily instigates this movement. As the ventricles contract, blood is forced into the prominent arteries, which then flow from areas of greater pressure to lower pressure areas. This movement continues into smaller arteries and arterioles and...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...